New Jersey And Philadelphia

HOBOKEN, New Jersey and PHILADELPHIA, September 20, 2011 - Niiki Pharma Inc.

HOBOKEN, New Jersey and PHILADELPHIA, June 1, 2011 - - Phase I Data for NKP-1339, a First-in-Class Transferrin Targeted Anti-Cancer Agent to be Presented at Upcoming American Society of Clinical Oncology Annual Meeting Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.